| | | | |
CUSIP No. 92790C104 | | Schedule 13G | | Page 7 of 12 |
ITEM 1. | (a) Name of Issuer |
Viridian Therapeutics, Inc., successor by merger to Miragen Therapeutics, Inc. (the “Issuer”).
| (b) | Address of Issuer’s Principal Executive Offices: |
221 Crescent Street, Suite 401
Waltham, MA 02453
ITEM 2. | (a) Name of Person Filing: |
Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:
Ally Bridge MedAlpha Master Fund L.P. (“MedAlpha”)
Ally Bridge MedAlpha Management L.P.
Ally Bridge MedAlpha Management GP, LLC
Ally Bridge Group (NY) LLC
ABG Management Ltd.
Mr. Fan Yu
| (b) | Address or Principal Business Office: |
The address for each of MedAlpha, Ally Bridge MedAlpha Management L.P., Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC is 430 Park Avenue, 12th Floor, New York, NY 10022
The address for each of the other Reporting Persons is Unit 3002-3004, 30th Floor, Gloucester Tower, The Landmark, 15 Queen’s Road Central, Hong Kong.
| (c) | Citizenship of each Reporting Person is: |
Ally Bridge Group (NY) LLC is an entity organized under the laws of the State of Delaware. Mr. Fan Yu is a citizen of Hong Kong. Each of the other Reporting Persons is organized under the laws of the Cayman Islands.
| (d) | Title of Class of Securities: |
Common stock, $0.01 par value (“Common Stock”).
92790C104